Clinique De La Sauvegarde

Lyon 19 trials 11 recruiting

19 Registered trials

11 Currently recruiting

Organisation

Clinique De La Sauvegarde

Location

Lyon, France

Identifier

ORG-100042695

Address

Avenue David Ben Gourion Lieudit, 69009, France

Departments

Anesthésie et Réanimation
Anesthésie-réanimation
Chirurgie digestive
hematology
Medical Oncology
Oncologie
Oncologie médicale
Oncology

Clinical trials at this site (19)

Search interface

ESP-BACK : Erector Spinae Plane Block for acute low back pain Pending

2024-511595-32-00 Acute low back pain 6
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting

2024-515118-42-00 Colorectal cancer 11 2024-09-10
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANC 4 2024-07-18
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch… Recruiting

2023-505660-11-00 Cholangiocarcinoma (LTT, 26.0) 5 2024-04-24
Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc… Recruiting

2023-506885-30-00 Adult patients with intermediate low or mid rectal aden 5 2024-03-26
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for… Recruiting

2024-511904-18-00 Pancreatic adenocarcinoma (PAC) 10 2020-07-08
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting

2023-508072-11-00 Castration-resistant prostate cancer 5 2019-06-26
Evaluating the superiority of VAsopressin versus NOradrenaline in the management of the renal risk patient undergoing cardiac surgery with e… Ended

2022-500419-38-00 vasoplegic syndrome 5 2022-12-28
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4